Literature DB >> 9192760

The missense mutation Arg593 --> Cys is related to antibody formation in a patient with mild hemophilia A.

K Fijnvandraat1, E A Turenhout, E N van den Brink, J W ten Cate, J A van Mourik, M Peters, J Voorberg.   

Abstract

The development of inhibitory antibodies to factor VIII in patients affected by a mild form of hemophilia A (factor VIII > 0.05 IU/mL) is considered a rare event. In this study, we evaluated the relationship between genotype and anti-factor VIII antibody formation in a patient with mild hemophilia A. Mutation analysis showed that a missense mutation in the factor VIII gene leading to replacement of Arg593 by Cys in the A2 domain of factor VIII was associated with hemophilia A in this patient. The anti-factor VIII antibodies present in the patient's plasma were characterized using metabolically labeled factor VIII fragments expressed in insect cells. The anti-factor VIII antibodies, composed of subclasses IgG2 and IgG4, reacted with both the fragment corresponding to the factor VIII heavy chain and the A2 domain. The Arg593 --> Cys substitution was introduced into the cDNA encoding the A2 domain of factor VIII and the resulting construct was expressed in insect cells. Strikingly, the metabolically labeled A2 domain carrying the Arg593 --> Cys mutation was not recognized by the anti-factor VIII antibodies present in the plasma of the patient. These data indicate that the anti-factor VIII antibodies are exclusively directed against exogenous factor VIII. This strongly suggests that the Arg593 --> Cys substitution results in recognition of wild-type factor VIII as nonself and is thereby related to the formation of anti-factor VIII antibodies after factor VIII replacement therapy in this particular patient.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9192760

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P.

Authors:  R A Ettinger; E A James; W W Kwok; A R Thompson; K P Pratt
Journal:  Haemophilia       Date:  2010-05       Impact factor: 4.287

Review 2.  The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics.

Authors:  Zuben E Sauna; Jay N Lozier; Carol K Kasper; Chen Yanover; Timothy Nichols; Tom E Howard
Journal:  Blood       Date:  2014-11-18       Impact factor: 22.113

3.  T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site.

Authors:  E A James; S D van Haren; R A Ettinger; K Fijnvandraat; J A Liberman; W W Kwok; J Voorberg; K P Pratt
Journal:  J Thromb Haemost       Date:  2011-04       Impact factor: 5.824

4.  Rhesus monkeys and baboons develop clotting factor VIII inhibitors in response to porcine endothelial cells or islets.

Authors:  John M Stewart; Alice F Tarantal; Wayne J Hawthorne; Evelyn J Salvaris; Philip J O'Connell; Mark B Nottle; Anthony J F d'Apice; Peter J Cowan; Mary Kearns-Jonker
Journal:  Xenotransplantation       Date:  2014-05-08       Impact factor: 3.907

Review 5.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

6.  Specific and global coagulation tests in patients with mild haemophilia A with a double mutation (Glu113Asp, Arg593Cys).

Authors:  Alenka Trampuš Bakija; Maruša Debeljak; Irena Preložnik Zupan; Majda Benedik Dolničar; Jernej Kovač; Janez Jazbec
Journal:  Blood Transfus       Date:  2015-05-15       Impact factor: 3.443

Review 7.  Characterization of factor VIII inhibitors.

Authors:  Midori Shima
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

8.  Low-dose continuous infusion of factor VIII in patients with haemophilia A.

Authors:  Tomaž Prelog; Majda Benedik Dolničar; Lidija Kitanovski
Journal:  Blood Transfus       Date:  2015-11-16       Impact factor: 3.443

9.  Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: a computational assessment.

Authors:  Gouri Shankar Pandey; Chen Yanover; Tom E Howard; Zuben E Sauna
Journal:  PLoS Comput Biol       Date:  2013-05-16       Impact factor: 4.475

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.